|Bid||38.76 x 1200|
|Ask||38.75 x 800|
|Day's Range||38.20 - 38.87|
|52 Week Range||31.69 - 42.82|
|Beta (3Y Monthly)||0.17|
|PE Ratio (TTM)||27.57|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.25|
We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Dr. Reddy's Laboratories Limited (NYSE:RDY) based on […]
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter store-brand equivalent of Prevacid® 24HR Capsules, in the United States market, as approved by the U.S.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® for injection, approved by the U.S.
Dr. Reddy’s Laboratories Ltd announced that the Company will be presenting at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, 2019, in New York City.
We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.